| These data identify Aletrnative splicing programs controlled by ZRANB2 and SYF2 and converging on ECT2, that participate to breast cancer cell resistance to doxorubicin. | ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin.
Tanaka I, Chakraborty A, Saulnier O, Benoit-Pilven C, Vacher S, Labiod D, Lam EWF, Bièche I, Delattre O, Pouzoulet F, Auboeuf D, Vagner S, Dutertre M., Free PMC Article | 05/23/2020 |
| ZRANB2 is part of the supraspliceosome and causes differential splicing of numerous primary transcripts, some of which might have a role in cancer. | ZRANB2 localizes to supraspliceosomes and influences the alternative splicing of multiple genes in the transcriptome.
Yang YH, Markus MA, Mangs AH, Raitskin O, Sperling R, Morris BJ. | 03/15/2014 |
| sites responsible for MRNA binding have been characterized. | The structure of the zinc finger domain from human splicing factor ZNF265 fold.
Plambeck CA, Kwan AH, Adams DJ, Westman BJ, van der Weyden L, Medcalf RL, Morris BJ, Mackay JP. | 01/21/2010 |